Published in Am J Med on November 01, 1991
Didanosine and zidovudine resistance patterns in clinical isolates of human immunodeficiency virus type 1 as determined by a replication endpoint concentration assay. Antimicrob Agents Chemother (1992) 1.22
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. Antimicrob Agents Chemother (1995) 0.81
In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother (1996) 0.79
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science (1985) 7.70
Ecology. Synthesizing U.S. river restoration efforts. Science (2005) 7.26
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
Evolution of organic aerosols in the atmosphere. Science (2009) 4.82
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science (1987) 4.31
Designing CD4 immunoadhesins for AIDS therapy. Nature (1989) 4.00
Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science (1985) 3.81
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Human T lymphotropic virus type III infection of human alveolar macrophages. Blood (1986) 3.66
Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist (2000) 3.62
HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science (1984) 3.50
The acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.49
HTLV-III in cells cultured from semen of two patients with AIDS. Science (1984) 3.47
Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med (1992) 3.30
Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol (1997) 3.27
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science (1985) 3.05
A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med (1989) 2.95
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
Immunity to influenza in ferrets. I. Response to live and killed virus. Br J Exp Pathol (1972) 2.78
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med (1990) 2.52
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Association of human T lymphotropic virus type III antibodies with sexual and other behaviors in a cohort of homosexual men from Boston with and without generalized lymphadenopathy. Am J Med (1986) 2.33
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med (1987) 2.31
Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer (1998) 2.29
Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet (1982) 2.28
Intra-blood-brain-barrier synthesis of HTLV-III-specific IgG in patients with neurologic symptoms associated with AIDS or AIDS-related complex. N Engl J Med (1985) 2.20
Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem (1995) 2.17
Biological properties of a CD4 immunoadhesin. Nature (1990) 2.05
Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature (1987) 1.91
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med (1990) 1.89
Seroepidemiology of human T-lymphotropic virus type III among homosexual men with the acquired immunodeficiency syndrome or generalized lymphadenopathy and among asymptomatic controls in Boston. Ann Intern Med (1985) 1.89
Human T-lymphotropic virus type III in high-risk, antibody-negative homosexual men. Ann Intern Med (1986) 1.88
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol (1987) 1.83
The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study. Ann Intern Med (1990) 1.82
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med (1990) 1.81
Chemical and microphysical characterization of ambient aerosols with the aerodyne aerosol mass spectrometer. Mass Spectrom Rev (2007) 1.80
CD4+ lymphocyte function with early human immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 1.78
Immunity to influenza in ferrets. II. Influence of adjuvants on immunization. Br J Exp Pathol (1972) 1.70
A colorimetric assay for the measurement of the sensitivity of herpes simplex viruses to antiviral agents. Antiviral Res (1983) 1.69
A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group. J Hyg (Lond) (1975) 1.67
Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: a double-blind trial. Ann Intern Med (1982) 1.67
Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses (1987) 1.65
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest (1989) 1.61
Some aspects of immunity in patients with cystic fibrosis. Clin Exp Immunol (1974) 1.60
Weight loss methods used by African American and Euro-American women. Res Nurs Health (1997) 1.59
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin Pharmacol Ther (1991) 1.58
Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis (1982) 1.56
The histiocytic disorders: a pathophysiologic analysis. Ann Intern Med (1981) 1.50
Dispersal as a regional process affecting the local dynamics of marine and stream benthic invertebrates. Trends Ecol Evol (1996) 1.50
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem (2000) 1.46
Immune (gamma) interferon produced by a human T-lymphoblast cell line. Nature (1981) 1.45
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol (1993) 1.44
Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. J Infect Dis (1992) 1.44
Nutritional supplementation in treatment of cystic fibrosis of the pancreas. Am J Dis Child (1973) 1.44
Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol (1991) 1.41
Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med (1991) 1.41
HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood (2001) 1.40
Immunity to influenza in ferrets. VII. Effect of previous infection with heterotypic and heterologous influenza viruses on the response of ferrets to inactivated influenza virus vaccines. J Hyg (Lond) (1974) 1.40
Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4. J Virol (1989) 1.38
Behavioral risk factors for HIV infection among homosexual men at a Boston community health center. Am J Public Health (1988) 1.37
Low sensitivity of ELISA testing in early HIV infection. N Engl J Med (1986) 1.37
Immune complexes in cystic fibrosis. Br Med J (1975) 1.36
In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci U S A (1986) 1.35
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene (2009) 1.35
Hematologic manifestations of the human immune deficiency virus (HIV). Semin Hematol (1988) 1.34
HTLV-III infection among health care workers. Association with needle-stick injuries. JAMA (1985) 1.31
The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood (1998) 1.30
Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol (1998) 1.28
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells. J Virol (1990) 1.28
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood (1994) 1.26
Epidemic of the acquired immunodeficiency syndrome: a need for economic and social planning. Ann Intern Med (1983) 1.24
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin (2005) 1.24
Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis (1983) 1.23
Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol (1980) 1.23
Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection. J Clin Microbiol (1986) 1.22
Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep (1979) 1.22
Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol (1999) 1.21
CD4 immunoadhesin, but not recombinant soluble CD4, blocks syncytium formation by human immunodeficiency virus type 2-infected lymphoid cells. J Virol (1990) 1.20
Pathophysiology and management of HIV-associated hematologic disorders. Blood (1989) 1.20
Potentiation of the antibody response to inactivated A2-Hong Kong vaccines by previous heterotypic influenza virus infection. Microbios (1974) 1.18
Stromal cell-derived factor-1 alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. J Immunol (1998) 1.18
Pathogenesis of B cell lymphoma in a patient with AIDS. Blood (1986) 1.18